TY - JOUR AU - Powles, Thomas AU - Park, Se Hoon AU - Voog, Eric AU - Caserta, Claudia AU - Valderrama, Begoña P AU - Gurney, Howard AU - Kalofonos, Haralabos AU - Radulovic, Sinisa AU - Demey, Wim AU - Ullén, Anders AU - Loriot, Yohann AU - Sridhar, Srikala S AU - Tsuchiya, Norihiko AU - Kopyltsov, Evgeny AU - Sternberg, Cora N AU - Bellmunt, Joaquim AU - Aragon-Ching, Jeanny B AU - Petrylak, Daniel P AU - Laliberte, Robert J AU - Huang, Bo AU - Costa, Nuno AU - Blake-Haskins, John A AU - Grivas, Petros PY - 2022 DO - 10.2217/fon-2021-1631 UR - http://hdl.handle.net/10668/20493 T2 - Future oncology (London, England) AB - This is a plain language summary of an article originally published in The New England Journal of Medicine. It is about initial results (collected in October 2019) from the JAVELIN Bladder 100 study (a clinical trial), which looked at avelumab... LA - en KW - JAVELIN Bladder 100 KW - avelumab KW - bladder cancer KW - immunotherapy KW - lay summary KW - maintenance treatment KW - plain language summary KW - urothelial cancer KW - Antibodies, Monoclonal, Humanized KW - Carcinoma, Transitional Cell KW - Drug-Related Side Effects and Adverse Reactions KW - Humans KW - Language KW - Quality of Life KW - Urinary Bladder KW - Urinary Bladder Neoplasms TI - Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer. TY - research article VL - 18 ER -